
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb's positive outlook is supported by potential catalysts such as positive clinical data from the Cobenfy ADEPT-2 trial and anticipated faster growth in the company's Growth Portfolio, indicating strong revenue prospects. Additionally, positive developments in CD19 NEX-T data for broader autoimmune diseases could enhance their market position and lead to advancements into pivotal studies. Despite some recent negative optics regarding top-line data, underlying supportive trends and key opinion leader (KOL) feedback suggest sustained growth in drug usage, further reinforcing the company's growth trajectory.
Bears say
Bristol-Myers Squibb's recent announcement regarding the Cobenfy drug demonstrated disappointing top-line data, falling short of statistical significance in the adjunctive schizophrenia setting, which raises concerns about the drug's commercial viability. The company's reliance on a narrow segment of its late-stage pipeline, particularly the ADEPT-2 trial, introduces significant downside risks, including the potential for delays and negative results that could further impact future growth and sales. Furthermore, with approximately 70% of sales derived from the US market, Bristol's heavy dependence heightens vulnerability to local market fluctuations and competition, exacerbating the overall negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares